Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anebulo Pharmaceuticals, Inc.ANEB · Entity 9617 | Director | April 04, 2025 | April 08, 2025 |
| LIFECORE BIOMEDICAL, INC. \DE\LFCR · Entity 6447 | Director | July 08, 2024 | July 10, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anebulo Pharmaceuticals, Inc.
Report date April 04, 2025 · Filed April 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.02 · Expires 2035-04-03 | Direct | 25,000 |
Reported balance
After 2025-04-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-04-04 · Grant · Acquired 25,000 · Balance 25,000 F1: The option vests on the earlier of April 4, 2026 or the date of the 2026 annual meeting of shareholders. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.02 · Expires 2035-04-03 | Direct | 3,309 |
Reported balance
After 2025-04-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-04-04 · Grant · Acquired 3,309 · Balance 3,309 F1: The option vests on the earlier of April 4, 2026 or the date of the 2026 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of April 4, 2026 or the date of the 2026 annual meeting of shareholders.
LIFECORE BIOMEDICAL, INC. \DE\
Report date July 08, 2024 · Filed July 10, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,069 |
Reported balance
After 2024-07-08 transaction · row 1
1 source rowRow 1 · 2024-07-08 · Grant · Acquired 30,000 · Balance 58,069 F1: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2: Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
F2: Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 04, 2025 Filed Apr 8, 2025 01:41 UTC | Anebulo Pharmaceuticals, Inc. ANEB · Entity 9617 | GrantStock Option (right to buy) · Derivative | 3,309 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0001641172-25-003094 · ownership.xml · derivative · entry 2 Calloway Nathaniel · CIK 0001952771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,309 Underlying: Common Stock · 3,309 shares Expires 2035-04-03 F1 · derivative.exercise_date: The option vests on the earlier of April 4, 2026 or the date of the 2026 annual meeting of shareholders. Read SEC document |
| April 04, 2025 Filed Apr 8, 2025 01:41 UTC | Anebulo Pharmaceuticals, Inc. ANEB · Entity 9617 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0001641172-25-003094 · ownership.xml · derivative · entry 1 Calloway Nathaniel · CIK 0001952771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-04-03 F1 · derivative.exercise_date: The option vests on the earlier of April 4, 2026 or the date of the 2026 annual meeting of shareholders. Read SEC document |
| July 08, 2024 Filed Jul 10, 2024 23:52 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | GrantCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-031634 · wk-form4_1720655516.xml · nonDerivative · entry 1 Calloway Nathaniel · CIK 0001952771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,069 F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · price: Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:23 UTC | Anebulo Pharmaceuticals, Inc. ANEB · Entity 9617 | GrantStock Option (right to buy) · Derivative | 1,655 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001493152-24-024126 · ownership.xml · derivative · entry 2 Calloway Nathaniel · CIK 0001952771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,655 Underlying: Common Stock · 1,655 shares Expires 2034-06-12 F2 · derivative.exercise_date: These stock options vest on the earlier of November 30,2024 or the date of the 2024 annual meeting of shareholders Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:23 UTC | Anebulo Pharmaceuticals, Inc. ANEB · Entity 9617 | GrantStock Option (right to buy) · Derivative | 41,667 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001493152-24-024126 · ownership.xml · derivative · entry 1 Calloway Nathaniel · CIK 0001952771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,667 Underlying: Common Stock · 41,667 shares Expires 2034-06-12 F1 · derivative.exercise_date: These stock options vest 50% on the date of the 2024 annual meeting of shareholders and 50% on the one year anniversary of the date of grant Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 23:41 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | Exercise / conversionRestricted Stock Unit · Derivative | 3,981 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-003139 · wk-form4_1706917311.xml · derivative · entry 2 Calloway Nathaniel · CIK 0001952771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,981 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · derivative.expiration_date: The restricted stock units vested on February 1, 2024. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 23:41 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | Exercise / conversionCommon Stock | 3,981 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-003139 · wk-form4_1706917311.xml · nonDerivative · entry 1 Calloway Nathaniel · CIK 0001952771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,069 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 00:14 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | Exercise / conversionRestricted Stock Unit · Derivative | 5,906 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-001074 · wk-form4_1704932063.xml · derivative · entry 2 Calloway Nathaniel · CIK 0001952771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,906 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · derivative.expiration_date: The restricted stock units vested on January 9, 2024. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 00:14 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | Exercise / conversionCommon Stock | 5,906 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-001074 · wk-form4_1704932063.xml · nonDerivative · entry 1 Calloway Nathaniel · CIK 0001952771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,088 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 19:19 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | GrantCommon Stock | 18,182 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-020835 · wk-form4_1685992772.xml · nonDerivative · entry 1 Calloway Nathaniel · CIK 0001952771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,182 F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · price: Restricted Stock Units will vest and be settled on the earlier of the 1st anniversary of the grant date or the date of the 2024 Annual Meeting of Stockholders (provided such date is no less than 50 weeks from Grant Date). Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 22:30 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | GrantRestricted Stock Unit · Derivative | 3,981 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-002097 · wf-form4_167537701261314.xml · derivative · entry 1 Calloway Nathaniel · CIK 0001952771 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,981 Underlying: Common Stock · 3,981 shares Expires not disclosed F1 · derivative.exercise_price: The Restricted Stock Units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F1 · price: The Restricted Stock Units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document |
| January 09, 2023 Filed Jan 11, 2023 21:21 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | GrantRestricted Stock Unit · Derivative | 5,906 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-000899 · wf-form4_167347208527160.xml · derivative · entry 1 Calloway Nathaniel · CIK 0001952771 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,906 Underlying: Common Stock · 5,906 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document |
| November 01, 2022 Filed Nov 2, 2022 20:31 UTC | Anebulo Pharmaceuticals, Inc. ANEB · Entity 9617 | GrantStock Option (right to buy) · Derivative | 59,149 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-22-055300 · doc4.xml · derivative · entry 1 Calloway Nathaniel · CIK 0001952771 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,149 Underlying: Common Stock · 59,149 shares Expires 2027-10-31 F1 · derivative.exercise_date: 25% of the original number of shares vest on the first anniversary of November 1, 2022 (the "Vesting Commencement Date") and 2.0833% of the original number of shares vest at the end of each successive month following the first anniversary of the Vesting Commencement Date until the fourth anniversary of the Vesting Commencement Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.